> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panels to Discuss KenPharm Abuse-Deterrent Pain Product
- URL: https://www.fdaweb.com/panels-to-discuss-kenpharm-abuse-deterrent-pain-product/
- Published: 2016-03-15T12:00:00.000Z
- Updated: 2026-09-15T02:43:41.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135094

*Federal Register* Notice: FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet 5/5, from 8 a.m. to 5 p.m. at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committees will be asked to discuss a KenPharm, Inc. NDA for benzhydrocodone/acetaminophen oral tablets for short-term (up to 14 days) management of acute pain. The product has been formulated with the intent to provide abuse-deterrent properties. Benzhydrocodone is a hydrocodone prodrug which, according to the applicant, is rapidly converted into hydrocodone by enzymes in the gastrointestinal tract. The committees will be asked to discuss whether the applicant has demonstrated abuse-deterrent properties for their product that would support labeling, and whether the nasal route of abuse is relevant for combination products made up of hydrocodone and acetaminophen. Contact **Stephanie L. Begansky**, (301) 796-9001\. To view this notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-03-15/pdf/2016-05748.pdf?ref=fdaweb.com).